Clinical Trials Logo

Clinical Trial Summary

Ventricular repolarization, measured by corrected QT interval (QTc), is influenced by sex hormones. A QTc above 460msec predisposes to the risk of "torsades-de-pointes"(TdP). The investigators have recently shown that estradiol determines an increase in QTc elongation and progesterone shortens it. In addition, high gonadotropin levels (FSH or LH) are associated with QTc prolongation. Hypergonadotropic hypogonadisms (low progesterone and high gonadotropins) are therefore hormonal situations that promote QTc prolongation. Premature ovarian insufficiency (POI) is one of them. Its management is based on the prescription of hormone replacement therapy (HRT). Epidemiological studies have shown that these patients would be at increased risk of cardiovascular mortality. Our team is interested in the effect of this pathological hormonal situation and its HRT on ventricular repolarization in order to define whether this is a population at risk for long QTc.


Clinical Trial Description

Ventricular repolarization, measured by the duration of the heart rate corrected QT interval (QTc), is influenced by sex hormones. A QTc above 460msec predisposes to the risk of torsades-de-pointes (TdP); ventricular arrhythmias that can lead to sudden death. From puberty to menopause, QTc is longer in women than in men (~10-15msec difference) and varies in women according to the menstrual cycle (~5-10msec). This explains the increased risk of TdP in women compared to men. During the menstrual cycle, the risk is highest for women during the follicular phase compared to the luteal phase. The investigators have recently shown that estradiol determines an increase in QTc elongation and progesterone shortens it. In addition, high gonadotropin levels (FSH or LH) are associated with QTc prolongation. Hypergonadotropic hypogonadisms (low progesterone and high gonadotropins) are therefore hormonal situations that promote QTc prolongation. Premature ovarian insufficiency (POI) affects 1% of women under 40 years of age and is characterized by hypergonadotropic hypogonadism. POI is associated with hormonal deficiencies responsible for amenorrhea and infertility. Management is based on the prescription of hormone replacement therapy (HRT). Epidemiological studies have shown that these patients would be at increased risk of cardiovascular mortality. HRT will be based on the combination of an estrogen and a progestin and will lead to a variable decrease in gonadotropins, depending on the steroid hormones/doses used. Our team, after structuring one of the largest international cohorts of patients with POI, is interested in the effect of this pathological hormonal situation and its HRT on ventricular repolarization to define whether this is a population at risk for long QTc. Indeed, ECG follow-up is recommended and many drugs (cardiovascular or not), are to be avoided, or even contraindicated in situations at risk of long QTc. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04167033
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Anne Bissery, MD
Phone 1 42 16 24 32
Email anne.bissery@aphp.fr
Status Recruiting
Phase N/A
Start date April 14, 2021
Completion date April 13, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06072794 - A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI) Phase 1
Recruiting NCT06096766 - the Correlation Between Ovarian Function and Serum Biomarkers
Completed NCT04641624 - sFlt- 1, PIGF, and Niacin Levels in Women With Premature Ovarian Insufficiency
Recruiting NCT05308342 - Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency N/A
Not yet recruiting NCT06067529 - A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency
Recruiting NCT05665010 - Precise Stratification of Genetic Risk of Ovarian Function Impairment
Not yet recruiting NCT05385848 - Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study N/A
Completed NCT04475744 - 4-step ASCOT in POI Women to Promote Follicular Rescue Phase 3
Recruiting NCT05279560 - Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation N/A
Recruiting NCT06302543 - Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells N/A
Recruiting NCT06145061 - Evaluation on Biological Characteristics of Acupoints in Premature Ovarian Insufficiency
Recruiting NCT05858307 - Clinical Application of Serum Anti-Müllerian Hormone (AMH) Measurements
Completed NCT06228547 - Women's Experience of Premature Ovarian Insufficiency (POI) Diagnosis: Update on Actual Practices and Patient's Follow up
Recruiting NCT06102655 - Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics Early Phase 1
Recruiting NCT05485610 - Effect of NMN (Nicotinamide Mononucleotide) on Diminished Ovarian Reserve (Including Premature Ovarian Insufficiency) N/A
Recruiting NCT05586737 - Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency Phase 2
Not yet recruiting NCT06339489 - The Bone Metabolism Characteristics of Premature Ovarian Insufficiency